A New Supreme Court Ruling on Drug Liability

被引：2
|
作者：
Johnston, Mitchell C. [1 ]
Boumil, Marcia M. [2 ]
Curfman, Gregory [3 ]
机构：
[1] Yale Law Sch, New Haven, CT USA
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
[3] JAMA, 330 N Wabash Ave, Chicago, IL 60611 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2019年 / 322卷 / 07期
关键词：
D O I：
10.1001/jama.2019.8515
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In May 2019 the US Supreme Court sent back to lower courts the question of whether Merck Sharpe & Dohme Corp was liable for atypical fractures from its osteoporosis drug alendronate because it did not identify the adverse effect in the product's label. This Viewpoint discusses the legal questions of liability raised by the case and the implication of the decision for the pharmaceutical industry and for patients alleging harmed from prescription drugs.
引用
收藏
页码：607 / 608
页数：2
相关论文
共 50 条
12345